The #1 most cited and #1 largest open-access journal in Immunology
This section invites a large spectrum of contributions in the areas of human and veterinary vaccines and molecular therapeutics against well-known and emerging pathogens that challenge human or animal health. We welcome articles on the development and evaluation of vaccines and molecular therapeutics against viral, bacterial and parasitic infections, including biodefense agents, neglected diseases, wildlife pathogens, and aquaculture/fish pathogens.
This section invites a large spectrum of contributions in the areas of human and veterinary vaccines and molecular therapeutics against well-known and emerging pathogens that challenge human or animal health. Topics of interest range from discovery science to pre-clinical research and development and clinical evaluation, with an emphasis on new tools and innovative concepts in prophyactic or therapeutic vaccination. We welcome articles on the development and evaluation of vaccines and molecular therapeutics against viral, bacterial and parasitic infections, including biodefense agents, neglected diseases, wildlife pathogens, and aquaculture/fish pathogens. The scope of the section covers vaccine engineering, design, formulation, adjuvants, delivery and testing, as well as novel approaches to the discovery and characterization of antigens or small molecules that may be the foundation for novel therapeutics, and the associated immunological evaluation.
Vaccines and molecular therapeutics have evolved considerably over the last few decades, with some outstanding successes but also with many disappointing results. The challenges posed by complex and evolving pathogens, and poorly understood host-pathogen interactions; the failure for many pathogens of traditional vaccine approaches; the speed of dissemination and transmission of existing and emerging pathogens; the need for rapid vaccine development, evaluation and approval in outbreak situations; the increasing threshold for vaccines safety; the potential offered by high dimensional omic-based technoliges; and the explosion of science around the discovery and application of small molecules in a therapeutic setting; have revolutionized the field of prophyactic or therapeutic vaccination and small molecule therapies.
The goal of Vaccines and Molecular Therapeutics is to present technological and conceptual advances, and challenge dogma, in all fundamental and translational aspects of vaccines and molecular therapeutics.
We welcome submissions in the following areas:
- the development of new tools or approaches for prophylactic or therapeutic vaccination and small molecule therapies
- vaccines against viral, bacterial or parasitic infections
- small molecular therapeutics against viral, bacterial or parasitic infections
- neonatal vaccines and vaccines for the elderly
- vaccine engineering and vaccine design
- vaccine delivery
- recombinant subunit, synthetic peptide, toxoid, viral vector, VLP. plasmid DNA or RNA vaccines
- live attenuated, inactivated or genetically modified vaccines
- nanovaccines and nanotechnology
- vaccine adjuvants and vaccine formulations
- preclinical animal models
- definition of novel target molecules for vaccines or therapeutics
- elucidation of immune mechanisms or immunological readouts
- systems vaccinology
- description of innovative methods, protocols or technology
To maximize options for disseminating your work, multiple article types are accepted for submission to this journal, including original research, methods articles, protocols, technology reports, reviews, perspectives, hypothesis and theory articles, and opinion articles. We encourage the free discussion and exposure of conflicting results, new concepts and hypotheses.
Indexed in: PubMed, PubMed Central, Scopus, Web of Science, Google Scholar, DOAJ, CrossRef
PMCID: coming soon for all published articles
Vaccines and Molecular Therapeutics welcomes submissions of the following article types: Case Report, Classification, Clinical Trial, Correction, Editorial, General Commentary, Hypothesis & Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Protocols, Review, Specialty Grand Challenge and Technology Report.
All manuscripts must be submitted directly to the section Vaccines and Molecular Therapeutics, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Vaccines and Molecular Therapeutics will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Immunology.